Loading...
•
Dec 31, 2022
Amneal Q4 2022 Earnings Report
Amneal's Q4 2022 financial results were announced, with net revenue increasing by 14% compared to the previous year. The company reported a GAAP net loss of $4 million, but adjusted net income reached $71 million. The adjusted diluted EPS was $0.23, a 35% increase from Q4 2021.
Key Takeaways
Amneal Pharmaceuticals reported a mixed Q4 2022, with increased net revenue but a net loss according to GAAP. Adjusted EBITDA and EPS showed strong growth, driven by new product launches, expansion of the AvKARE channel, and strong specialty product performance. The company provided 2023 financial guidance, expecting continued revenue and adjusted EBITDA growth.
Net revenue for Q4 2022 was $610 million, a 14% increase year-over-year.
GAAP net loss was $4 million, an improvement from the $6 million loss in Q4 2021.
Adjusted EBITDA increased by 26% to $154 million.
Adjusted diluted EPS rose by 35% to $0.23.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Specialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal provided its full year 2023 financial guidance, projecting net revenue between $2.25 and $2.35 billion and adjusted EBITDA between $500 and $530 million.
Positive Outlook
- Net revenue between $2.25 billion and $2.35 billion
- Adjusted EBITDA between $500 million and $530 million
- Adjusted diluted EPS between $0.40 and $0.50
- Operating cash flow between $200 million and $230 million
- Capital expenditures of $50 million to $60 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income